SPRAVATO™ (Esketamine) A nasal spray used for the treatment of resistant depression. CIII Nasal Spray is indicated, in conjunction with an oral antidepressant (AD), for the treatment of treatment-resistant depression (TRD) in adults. SPRAVATO™ is not approved as an anesthetic agent. The safety and effectiveness of SPRAVATO as an anesthetic agent have not been established. Patients with major depressive disorder (MDD) who have tried two or more antidepressant treatments didn’t get the desired results/improvements may have treatment-resistant depression and may be considered for the medicine. The medicine is a major breakthrough in treating the depression to some extent because it’s exceptionally swift acting and may work within hours as compared to other antidepressants on the market.